Dr. Judith A. Betts, MD
Nephrology (Kidney) (Nephrology Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Texas since 1986, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
TX license H0171 (first issued 1986; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 273 | 123 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 143 | 22 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 63 | 46 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 61 | 57 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 50 | 20 |
| Established patient office or other outpatient visit, 30-39 minutes | 50 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $254 in total to this clinician.
| Novo Nordisk Inc | $106 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $98.89 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.83 |
| Aurinia Pharma U.S., Inc. | $21.91 |
| Food and Beverage | $254 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $1,750,088 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961 - A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Hoffmann-la Roche Limited - Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT05248646 - Double blind study to determine efficacy of ASO Factor B in IgAN
Hoffmann-la Roche Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.